Skip to content
Triangle logo TriangleGet started
← Study library

NCT02666950 · REGISTRY CONDITION SEARCH

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-09-06

This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving WEE1 inhibitor AZD1775 works better with or without cytarabine in treating patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Complete Response Rate (CR or CRi) Per the National Comprehensive Cancer Network (NCCN) Guidelines or According to Specific Criteria From Expert Panels

→

outcome · POSTED

Clinical Benefit as Measured by the Number of Patients Who Were Not RBC Transfusion-dependent Post-Baseline

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Percentage of Participants With Grade 3 or Higher Adverse Events Considered At Least Possibly Related to Treatment

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Time to Progression, Defined as the Time From Registration to the Earliest Date of Documentation of Disease Progression

→

outcome · POSTED

Time to Response, Defined as the Time From Registration to the Earliest Date of Documentation of Response

→

outcome · NOT POSTED

Change in Biomarker Levels

→

outcome · NOT POSTED

Change in Patients' Reported Outcomes as Assessed by the Brief Fatigue Inventory (BFI)

→

outcome · NOT POSTED

Change in QOL as Assessed by the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire Core Questionnaire 30

→

outcome · NOT POSTED

Pharmacokinetic (PK) Parameters AUC of WEE1 Inhibitor AZD1775

→

outcome · NOT POSTED

Pharmacokinetic (PK) Parameters Vd of WEE1 Inhibitor AZD1775

→

outcome · NOT POSTED

Pharmacokinetic (PK) Parameters Cmax of WEE1 Inhibitor AZD1775

→

outcome · NOT POSTED

Pharmacokinetic (PK) Parameters Tmax of WEE1 Inhibitor AZD1775

→

outcome · NOT POSTED

Pharmacokinetic (PK) Parameters t1/2 of WEE1 Inhibitor AZD1775

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patient population (histological or cytologically confirmed diagnosis): * Untreated elderly (\> 60 years) AML if in the intermediate and poor-risk cytogenetic group and not candidates (as judged by treating doctor of medicine \[MD\]) for or willing to undergo standard induction therapy (i.e. elderly unfavorable cytogenetic AML) or any untreated AML age \> 65 years * Note: previous therapy with a hypomethylating agent (HMA) for a diagnosis of MDS is allowed * Relapsed or refractory AML (\>= 18 years) * Any MDS (\>= 18 years) having failed or been intolerant to prior hypomethylating agent (HMA) treatment * Failure is defined as any disease progression while on HMA, relapse after HMA treatment or no response after 4 cycles of 5-Azacitidine or decitabine * Patients with isolated 5q-/5q- syndrome must have failed, not tolerated, or lenalidomide in addition to having failed or been intolerant to HMA treatment * Note: patients with chronic myelomonocytic leukemia (CMML) and MDS/myeloproliferative neoplasms (MPN) overlap are allowed if meeting other study eligibility criteria * Note: for all patient groups, therapy as part of a plan as a bridge to transplant is allowed * Total bilirubin =\< 1.5 mg/dL (except Gilbert's syndrome or known hemolysis or leukemic infiltration) * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x upper limit normal (ULN) or \< 5 x ULN if organ involvement * Alkaline phosphatase \< 5 x ULN * Serum creatinine =\< 2 x ULN or 24 hour creatinine (Cr) clearance \> 30 ml/min * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Ability to provide informed written consent and be able to adhere to the study visit schedule and other protocol requirements * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Willing to provide blood and bone marrow aspirate samples for correlative research purposes * Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only * Men and women must be willing to use appropriate contraception throughout study and for 6 months after * Male patients who are sexually active with a female partner of childbearing potential must be either surgically sterilized or agree to use barrier contraception (ie, condoms) for the duration of study participation, and for 90 days after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physician * Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are \> 60 days from stem cell infusion, have graft-versus-host disease (GVHD) =\< grade 1 and are off immunosuppressive agents for \> 28 days at time of registration Exclusion Criteria: * Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection, known positive for active infectious hepatitis, type A, B or C (past infection allowed), or psychiatric illness/social situations that would limit compliance with study requirements; Note: ongoing infection controlled on antibiotics/antifungal/antiviral medications are allowed * Any of the following prior therapies: * Cytotoxic chemotherapy =\<14 days prior to registration * Immunotherapy =\< 14 days prior to registration * Biologic therapy (i.e. antibody therapies) =\< 14 days prior to registration * Radiation therapy =\<14 days prior to registration * Targeted therapies (i.e. kinase inhibitors, =\< 7 days or 5 half-life's whichever is shorter) • For steroids or other non-cytotoxics given for blast count control, patient must be off for \> 24 hours (hrs) before starting therapy; NOTE: hydroxyurea (HU) is allowed for blast count control throughout study * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =\< 14 days prior to registration * Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy * Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial * Any previous treatment with AZD1775 or allergic reactions to excipients of AZD1775 * Acute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation * Major surgery =\< 28 days prior to registration * Clinically significant heart disease, including the following: * Active severe angina pectoris within 3 months prior to registration * Acute myocardial infarction within 3 months prior to registration * New York Heart Association classification IV cardiovascular disease or symptomatic class III disease * Note: patients with any of the above may be allowed after discussion amongst the investigators including the principal investigator * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Subject has had prescription or non-prescription drugs or other products known to be sensitive cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued two weeks prior (alternatively 5 half lives if T1/2 is known) prior to day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study drug * NOTE: co-administration of aprepitant or fosaprepitant during this study is prohibited * Note: individual drugs exerting CYP interactions may be continued on a case by case basis if felt essential for patient management, after discussions and discretion of the treating physician * The preferred azole anti-fungal medication is fluconazole (alternatively posaconazole) which can be given during treatment with AZD1775 at the treating physician's discretion, however with dose reductions of AZD1775 by 25-75% (i.e. from AZD1775 200mg to 150 or 100mg) * Patients may not be on an inhibitor of breast cancer resistance protein (BCRP) * NOTE: AZD1775 is an inhibitor of breast cancer resistance protein (BCRP); the use of statins including atorvastatin which are substrates for BCRP are therefore prohibited and patients should be moved on to non-BCRP alternatives * Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from 7 days prior to the dose of study medication and during the entire study; NOTE: orange juice is allowed * Corrected QT interval (QTc) \> 470 msec (as calculated per institutional standards) at study entry or congenital long QT syndrome
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
    intervention Names
    1. Drug: Cytarabine
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    4. Other: Quality-of-Life Assessment
    5. Other: Questionnaire Administration
    6. Drug: WEE1 Inhibitor AZD1775
    label
    Arm B (cytarabine and WEE1 inhibitor AZD1775
    type
    EXPERIMENTAL
  2. description
    Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
    intervention Names
    1. Other: Laboratory Biomarker Analysis
    2. Other: Pharmacological Study
    3. Other: Quality-of-Life Assessment
    4. Other: Questionnaire Administration
    5. Drug: WEE1 Inhibitor AZD1775
    label
    Arm C (WEE inhibitor AZD1775)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm B (cytarabine and WEE1 inhibitor AZD1775
    description
    Given SC
    name
    Cytarabine
    other Names
    1. .beta.-Cytosine arabinoside
    2. 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
    3. 1-.beta.-D-Arabinofuranosylcytosine
    4. 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
    5. 1-Beta-D-arabinofuranosylcytosine
    6. 1.beta.-D-Arabinofuranosylcytosine
    7. 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
    8. 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
    9. Alexan
    10. Ara-C
    11. ARA-cell
    12. Arabine
    type
    DRUG
  2. arm Group Labels
    1. Arm B (cytarabine and WEE1 inhibitor AZD1775
    2. Arm C (WEE inhibitor AZD1775)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  3. arm Group Labels
    1. Arm B (cytarabine and WEE1 inhibitor AZD1775
    2. Arm C (WEE inhibitor AZD1775)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
  4. arm Group Labels
    1. Arm B (cytarabine and WEE1 inhibitor AZD1775
    2. Arm C (WEE inhibitor AZD1775)
    description
    Ancillary studies
    name
    Quality-of-Life Assessment
    other Names
    1. Quality of Life Assessment
    type
    OTHER
  5. arm Group Labels
    1. Arm B (cytarabine and WEE1 inhibitor AZD1775
    2. Arm C (WEE inhibitor AZD1775)
    description
    Ancillary studies
    name
    Questionnaire Administration
    type
    OTHER
  6. arm Group Labels
    1. Arm B (cytarabine and WEE1 inhibitor AZD1775
    2. Arm C (WEE inhibitor AZD1775)
    description
    Given PO
    name
    WEE1 Inhibitor AZD1775
    other Names
    1. AZD-1775
    2. AZD1775
    3. MK-1775
    4. MK1775
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
3
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Continuous biomarker levels will be explored in a graphical manner including mean plots and plots of change and percent change from baseline and other summary measures. Any potential relationships between the baseline level or change in the level of each biomarker and clinical outcome such as overall response, 6-month progression and survival, and adverse event incidence will be further analyzed using Wilcoxon rank sum tests or logistic regression methods, as appropriate. Association between a dichotomized biomarker and overall response will be assessed using a chi-squared test.
    measure
    Change in Biomarker Levels
    time Frame
    Baseline to up to 113 days (after course 4)
  2. description
    BFI, as well as linear analog scales capturing early satiety, abdominal discomfort, inactivity, concentration problems, numbness/tingling in the hands/feet, night sweats, itching, bone pain, fever, and weight loss will be used.
    measure
    Change in Patients' Reported Outcomes as Assessed by the Brief Fatigue Inventory (BFI)
    time Frame
    Baseline to 2 years
  3. description
    Scale score trajectories over time and changes from baseline over time will be examined using repeated measures or growth curve models, as appropriate, stream plots and mean plots with standard deviation error bars overall. Scores and changes at each cycle will be statistically tested using paired t-tests, and standardized response means (i.e. effect sizes) (mean of the change from baseline scores at a given cycle, divided by the standard deviation of the change scores) will be interpreted (after applying Middel's adjustment) using Cohen's cut-offs.
    measure
    Change in QOL as Assessed by the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire Core Questionnaire 30
    time Frame
    Baseline to 2 years
  4. description
    PK will be primarily descriptive.
    measure
    Pharmacokinetic (PK) Parameters AUC of WEE1 Inhibitor AZD1775
    time Frame
    Day 1, course 1; pre-treatment, 30 min, 1 hr, 2 hr, 4 hr, 6hr and 24 hr after WEE1 inhibitor AZD administration
  5. description
    PK will be primarily descriptive.
    measure
    Pharmacokinetic (PK) Parameters Vd of WEE1 Inhibitor AZD1775
    time Frame
    Day 1, course 1; pre-treatment, 30 min, 1 hr, 2 hr, 4 hr, 6hr and 24 hr after WEE1 inhibitor AZD administration
  6. description
    PK will be primarily descriptive
    measure
    Pharmacokinetic (PK) Parameters Cmax of WEE1 Inhibitor AZD1775
    time Frame
    Day 1, course 1; pre-treatment, 30 min, 1 hr, 2 hr, 4 hr, 6hr and 24 hr after WEE1 inhibitor AZD administration
  7. description
    PK will be primarily descriptive
    measure
    Pharmacokinetic (PK) Parameters Tmax of WEE1 Inhibitor AZD1775
    time Frame
    Day 1, course 1; pre-treatment, 30 min, 1 hr, 2 hr, 4 hr, 6hr and 24 hr after WEE1 inhibitor AZD administration
  8. description
    PK will be primarily descriptive
    measure
    Pharmacokinetic (PK) Parameters t1/2 of WEE1 Inhibitor AZD1775
    time Frame
    Day 1, course 1; pre-treatment, 30 min, 1 hr, 2 hr, 4 hr, 6hr and 24 hr after WEE1 inhibitor AZD administration
primary Outcomes
  1. description
    Complete response rate will be evaluated over all courses of study treatment. The proportion of CR/CRi responses will be estimated by the number of CR/CRi responses divided by the total number of evaluable patients.
    measure
    Complete Response Rate (CR or CRi) Per the National Comprehensive Cancer Network (NCCN) Guidelines or According to Specific Criteria From Expert Panels
    time Frame
    Up to 17 months
secondary Outcomes
  1. description
    Clinical benefit as measured by the number of patients who did not receive a RBC transfusion post-Baseline
    measure
    Clinical Benefit as Measured by the Number of Patients Who Were Not RBC Transfusion-dependent Post-Baseline
    time Frame
    Up to 17 months
  2. description
    Duration of response defined for all evaluable patients who have achieved a response as the date at which the patient's earliest best objective status is first noted to be a CR/CRi response to the earliest date progression is documented
    measure
    Duration of Response
    time Frame
    Up to 17 months
  3. description
    The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.
    measure
    Percentage of Participants With Grade 3 or Higher Adverse Events Considered At Least Possibly Related to Treatment
    time Frame
    Up to 30 days post-treatment
  4. description
    Overall survival time is defined as the time from registration to death due to any cause.
    measure
    Overall Survival
    time Frame
    From registration to death due to any cause, assessed up to 17 months
  5. description
    Time to progression (TTP) is defined to be the length of time from study registration to a) date of disease progression as defined by section 11.0 of the protocol, or b) last follow-up. If a patient dies without documentation of disease progression, the patient will be considered to have had a tumor progression at the time of death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Time to progression curves were compared via the log-rank test. Progression is defined as a \>25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians: appearance of new lesions compared to pretreatment MRI and/or CT scan.
    measure
    Time to Progression, Defined as the Time From Registration to the Earliest Date of Documentation of Disease Progression
    time Frame
    Up to 17 months
  6. description
    Time to response, defined as the time from registration to the earliest date of documentation of response. The distribution of time to progression will be estimated using the method of Kaplan-Meier.
    measure
    Time to Response, Defined as the Time From Registration to the Earliest Date of Documentation of Response
    time Frame
    Up to 17 months
Full study description
brief Summary
This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving WEE1 inhibitor AZD1775 works better with or without cytarabine in treating patients with advanced acute myeloid leukemia or myelodysplastic syndrome.
detailed Description
PRIMARY OBJECTIVES: I. To estimate the clinical efficacy of AZD1775 (WEE1 inhibitor AZD1775) in combination with AraC (cytarabine) in patients with newly diagnosed acute myeloid leukemia (AML) by assessing complete response (complete remission \[CR\] plus CR with incomplete blood count recovery \[CRi\]) rates. II. To estimate the clinical efficacy of AZD1775 alone or in combination with AraC in patients with relapsed/refractory AML and hypomethylating agent failure myelodysplastic syndrome (MDS) by assessing complete response (CR plus CRi) rates. SECONDARY OBJECTIVES: I. To determine the safety and tolerability of AZD1775 alone or combined with AraC in the study population. II. To estimate additional measures of clinical benefit (i.e. hematological improvements, transfusion requirements). III. To measure the duration of response of AZD1775 alone or combined with AraC. IV. To measure time to response of AZD1775 alone or combined with AraC. V. To measure time to progression of AZD1775 alone or combined with AraC. VI. To measure overall survival of AZD1775 alone or combined with AraC. VII. To measure time to AML (for MDS subjects) of AZD1775 alone or combined with AraC. TERTIARY OBJECTIVES: I. To determine the pharmacokinetics (PK) of AZD1775 alone or combined with AraC in the study population. II. To conduct correlative research studies characterizing underlying molecular events and solidifying putative mechanism of action in vivo and to identify potential pharmacodynamic/biomarkers of response to AZD1775 alone or combined with AraC. III. To evaluate quality of life (QOL) and patient-reported symptoms in subjects treated with AZD1775 alone or combined with AraC. OUTLINE: Elderly newly diagnosed patients are assigned to arm A. ARM A (ELDERLY NEWLY DIAGNOSED PATIENTS): Patients receive cytarabine subcutaneously (SC) twice daily (BID) on days 1-5 and 8-12 and WEE inhibitor AZD1775 orally (PO) daily on days 1-5 and 8-12. Patients are randomized to 1 of 2 treatment arms. ARM B: Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A. ARM C: Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26. In all arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3-6 months for 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-048cbe038948baa4b7fa
      requested nct id
      NCT02666950
      primary nct id
      NCT02666950
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      13884dd162605837649957fdcc712436de0d0f8244bc787fdbf12531ae5a1fb2
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-048cbe038948baa4b7fa
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02666950
      occurrences
      1. context exact
        NCT02666950
        end
        11
        exact text
        NCT02666950
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/122/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e7366a8777eaa207e7b6368b88f530d05d1f503ceca08968b91cafb6cbe2d1a6

    Preserved source evidence · Not medical advice